FBN1 and myeloid sarcoma: Taking into account the genetic heterogeneity present in patients with MS, the screening of FBN1 mutations should include both common techniques for the detection of exonic mutations, as well as methods for the detection of large deletions/insertions (Multiplex Ligation-dependent Probe Amplification, MLPA) and even for deep intronic mutations (whole genome sequencing, WGS) [47,61].